News & Updates

Show Multimedia Only

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

13 Dec 2025 by

Combination treatment with sodium bicarbonate plus diphenhydramine may provide better symptom relief for patients with acute peripheral vertigo compared with diphenhydramine alone, as shown in a study.

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

13 Dec 2025

Steatotic liver disease common in people with metabolic, alcohol risk factors

13 Dec 2025 by

Steatotic liver disease (SLD) appears to be highly prevalent among individuals with cardiometabolic or alcohol risk factors, while elevated liver stiffness and advanced liver fibrosis are not uncommon, reports a recent study.

Steatotic liver disease common in people with metabolic, alcohol risk factors

13 Dec 2025

Vedolizumab better used in early- vs late-stage Crohn’s disease

13 Dec 2025

In patients with Crohn’s disease (CD), initiating treatment with vedolizumab early than late in the disease course may lead to better safety and efficacy outcomes, according to a phase IV open-label cohort study.

Vedolizumab better used in early- vs late-stage Crohn’s disease

13 Dec 2025

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

In young children with type 1 diabetes (T1D), bedtime snacking appears to result in higher nocturnal glucose values and reduced time in range (TIR), without decreasing the frequency of hypoglycaemia, according to a randomized controlled crossover trial.

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025 by

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025 by

Both patients and healthcare professionals prefer treatment for asthma attacks that avoids the side effects of oral corticosteroids (OCS), and both are willing to trade off benefits, according to a study.

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025

MMP-9 tied to faster lung function decline, COPD development

12 Dec 2025

An elevated matrix metalloproteinase-9 (MMP-9) appears to cause lung function decline and the development of chronic obstructive pulmonary disease (COPD), suggests a study.